REVB: Revelation Biosciences Corp Average Forecast Price
Revelation Biosciences is developing treatments for infections and allergies, focusing on the wellness sector. The business operates on a virtual model where production and testing are outsourced to third-party contractors, yet patent ownership eliminates dependence on partners. The current metric stands at 123.94, as confirmed by the shares on this price chart, reflecting the price action of this immunological biotech company.
Analytical breakdowns for Revelation Bio (REVB)
- share price and consensus valuation forecast:
- market capitalization information:
- shareholders' equity book value data:
- business debt structure and liquidity details:
Aggregate Debt to Equity Revelation Biosciences|REVB - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Revelation Biosciences Corp|REVB - Company Aggregate Debts|Debts to Book Capitalization Revelation Bio|REVB - Company Long-Term Debt|Company Short-Term Loans and Borrowings Revelation Biosciences|Quick Liquidity Indicator revbiosciences.com
- financial results and valuation multiples details:
REVB - Net Profit|Projected Future Earnings Revelation Biosciences|REVB - Price to Earnings Ratio|Future Price to Earnings Multiple Revelation Biosciences Inc|REVB - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Revelation Bio|REVB - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Revelation Biosciences|REVB - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months revbiosciences.com|REVB - Net earnings per share growth this year|Earnings growth forecast for next year Revelation Biosciences
General company analysis:REVB revbiosciences.com
The specificity of Revelation Biosciences (REVB) lies in the potential for a margin surge as the company transitions from costly clinical trials to scalable production via contract laboratories. The consensus target price aggregates weighted estimates from investment banks, transforming future earnings expectations into a mechanical fair value benchmark, which allows investors to identify trend reversal points and balance the risk of a drawdown against the cost of missed opportunities.
Competitors of Revelation Biosciences
ARGX (argenx.com) - Fair Value Consensus|Analyst Consensus Forecast BNTX (BioNTech)|Abivax SA (ABVX) - Average Forecast Price|ADMA: Consensus Target|PTGX: Price Target Chart|IMVT: Analyst Consensus Forecast|KNSA (kiniksa.com) - Price Target Chart|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|JBIO - Price Target Chart|Fair Value Consensus ACRS (Aclaris Therapeutics, Inc)|KYTX: Analyst Consensus Forecast|Average Forecast Price tizianalifesciences.com (TLSA)|Consensus Target CABA|Price Target Chart VTYX|Analyst Consensus Forecast THTX|AVTX - Average Forecast Price|Price Target Chart Eledon Pharmaceuticals ELDN|agenusbio.com - Price Target Chart|Climb Bio - Analyst Consensus Forecast|ZURA - Analyst Consensus Forecast|ATYR (aTyr) - Consensus Target|ADAG: Analyst Forecast Prices|IMA (ImageneBio) - Analyst Consensus Forecast|Shattuck Therapeutics (STTK) - Analyst Median Target|Price Target Chart Equillium, Inc. (EQ)|CNTB - Average Forecast Price|Price Target Chart Immunic IMUX|ATRA: Broker Consensus Forecast|IFRX: Consensus Target|Fair Value Consensus XFOR (x4pharma.com)|ACET: Analyst Consensus Forecast|CELU (Celularity) - Price Target Chart|INMB (INmune Bio Corp) - Analyst Consensus Forecast|Barinthus Biotherapeutics Corp (BRNS) - Analyst Median Target|Price Target Chart Kezar Life Sciences (KZR)|SABS - Average Forecast Price|Price Target Chart Akari Therapeutics Plc AKTX|Analyst Median Target Enlivex Therapeutics Ltd (ENLV)|Q32 Bio Corp - Analyst Consensus Forecast|GeoVax Corp (GOVX) - Consensus Target|EDSA: Analyst Consensus Forecast|IBIO - Analyst Median Target|CARM (Carisma Therapeutics Inc) - Analyst Consensus Forecast|Average Forecast Price XTL Biopharmaceuticals Ltd XTLB|Price Target Chart Bolt Biotherapeutics (BOLT)|hcwbiologics.com - Broker Consensus Forecast|Analyst Consensus Forecast APVO (Aptevo Therapeutics Inc.)|AIM - Consensus Target|Aditxt Corp - Analyst Consensus Forecast|Average Forecast Price GRI Bio Inc|XORTX (XRTX) - Price Target Chart|HIND - Analyst Median Target|Price Target Chart Indaptus Therapeutics|SCNI: Fair Value Consensus|Analyst Consensus Forecast CALI|AFMD - Average Forecast Price|Allakos - Consensus Target|HOOKIPA Pharma, Inc. - Price Target Chart|IGM Bio - Analyst Consensus Forecast|ITOS: Price Target Chart|Ocean Biomedical (OCEA) - Price Target Chart|Forecast Levels Chart TCBP (TC BioPharm (Holdings) Plc)|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
